This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Illnait-Zaragozi, M.-T.
Right arrow Articles by Meis, J. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Illnait-Zaragozi, M.-T.
Right arrow Articles by Meis, J. F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2008, p. 1580-1582, Vol. 52, No. 4
0066-4804/08/$08.00+0     doi:10.1128/AAC.01384-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

In Vitro Activity of the New Azole Isavuconazole (BAL4815) Compared with Six Other Antifungal Agents against 162 Cryptococcus neoformans Isolates from Cuba{triangledown}

Maria-Teresa Illnait-Zaragozi,1,2 Gerardo F. Martínez,2 Ilse Curfs-Breuker,1 Carlos M. Fernández,2 Teun Boekhout,3 and Jacques F. Meis1*

Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands,1 Department of Medical Microbiology, Laboratory of Mycology, Institute of Tropical Medicine Pedro Kouri, Havana, Cuba,2 Centraalbureau voor Schimmelcultures, Utrecht, The Netherlands3

Received 26 October 2007/ Returned for modification 19 November 2007/ Accepted 11 January 2008

Cuban Cryptococcus isolates (n = 165) were tested in vitro against amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole, giving MIC90 values of 0.25, 8, 4, 0.25, 0.125, 0.016, and 0.016 µg/ml, respectively. Isavuconazole and posaconazole seem to be potentially active drugs for treating cryptococcal infections.

* Corresponding author. Mailing address: Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, P.O. Box 9015, 6500 GS Nijmegen, The Netherlands. Phone: 31243657514. Fax: 31243657516. E-mail: j.meis{at}cwz.nl

{triangledown} Published ahead of print on 22 January 2008.

Antimicrobial Agents and Chemotherapy, April 2008, p. 1580-1582, Vol. 52, No. 4
0066-4804/08/$08.00+0     doi:10.1128/AAC.01384-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Schmitt-Hoffmann, A., Roos, B., Spickermann, J., Heep, M., Peterfai, E., Edwards, D. J., Stoeckel, K. (2009). Effect of Mild and Moderate Liver Disease on the Pharmacokinetics of Isavuconazole after Intravenous and Oral Administration of a Single Dose of the Prodrug BAL8557. Antimicrob. Agents Chemother. 53: 4885-4890 [Abstract] [Full Text]  
  • Majithiya, J., Sharp, A., Parmar, A., Denning, D. W., Warn, P. A. (2009). Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei. J Antimicrob Chemother 63: 161-166 [Abstract] [Full Text]  
  • Thompson, G. R. III, Fothergill, A. W., Wiederhold, N. P., Vallor, A. C., Wickes, B. L., Patterson, T. F. (2008). Evaluation of Etest Method for Determining Isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans. Antimicrob. Agents Chemother. 52: 2959-2961 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»